Edwards Lifesciences
852 hedge funds and large institutions have $30.6B invested in Edwards Lifesciences in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 271 increasing their positions, 324 reducing their positions, and 70 closing their positions.
53% more call options, than puts
Call options by funds: $374M | Put options by funds: $244M
30% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 70
20% more capital invested
Capital invested by funds: $25.6B → $30.6B (+$5.03B)
5% more funds holding in top 10
Funds holding in top 10: 22 → 23 (+1)
1.97% more ownership
Funds ownership: 249.83% → 251.8% (+2%)
2% more funds holding
Funds holding: 838 → 852 (+14)
16% less repeat investments, than reductions
Existing positions increased: 271 | Existing positions reduced: 324
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$324M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$214M |
| 3 |
Janus Henderson Group
London,
|
+$198M |
| 4 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$105M |
| 5 |
Jennison Associates
New York
|
+$87.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$123M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$86.6M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$79.7M |
| 4 |
Renaissance Technologies
New York
|
-$72M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
-$66.3M |
EW Hedge Fund Activity: Q3 2018 in Review
852 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2018, worth a combined $30.6B — up 20% from $25.6B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new EW positions and 70 closed out — a net gain of 21 holders — while 271 added to existing stakes and 324 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $324M. The largest seller was Fidelity Investments, cutting an estimated $123M.
- 852 institutional investors held Edwards Lifesciences (EW) as of Q3 2018, up from 838 in Q2 2018.
- Funds reported $30.6B of Edwards Lifesciences stock for Q3 2018, up 20% quarter-over-quarter.
- 91 funds opened new Edwards Lifesciences positions in Q3 2018 and 70 closed out, a net change of +21 holders.
- The largest Edwards Lifesciences buyer in Q3 2018 was Capital Research Global Investors, an estimated $324M added.
- The largest Edwards Lifesciences seller in Q3 2018 was Fidelity Investments, an estimated $123M sold.
Based on aggregated 13F filings for Q3 2018.